Who is sponsoring NCT05525507?

NCT05525507 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT05525507?

Interventions in NCT05525507: Conditioning and Stem cell infusion.

What condition does NCT05525507 study?

NCT05525507 studies End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases.

Is NCT05525507 still recruiting?

NCT05525507 is currently recruiting now. Last updated 21 November 2025.

Last reviewed 2025-11-21 · How we verify

NCT05525507

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-armed, Unblinded, Non-randomized Feasibility Study of Hematopoietic Stem Cell Infusion Following a Conditioning Regimen of Total Lymphoid Irradiation (TLI) and Anti-thymocyte Globulin (ATG) in Patients With a Pre-existing, Well-functioning HLA-matched Kidney Transplant

Recruiting now Phase 1 Last updated 21 November 2025

What this trial tests

Phase 1 trial testing Conditioning and Stem cell infusion in End Stage Kidney Disease in 10 participants. Currently enrolling.

Timeline

21 December 2022

Primary endpoint
1 December 2026

1 December 2026

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	21 December 2022
Primary completion	1 December 2026
Estimated completion	1 December 2026
Sites	1 location across United States

Drugs / interventions tested

Conditioning and Stem cell infusion

Conditions studied

End Stage Kidney Disease — all drugs for End Stage Kidney Disease →
Immunological Tolerance — all drugs for Immunological Tolerance →
Kidney Transplant Failure and Rejection — all drugs for Kidney Transplant Failure and Rejection →
Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →

Sponsor

University of California, Los Angeles

Who can join

18 and older, any sex, with End Stage Kidney Disease or Immunological Tolerance. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Incidence of successful discontinuation of immunosuppression
Time frame: 12 months
To determine whether patients with pre-existing kidney transplants from a haploidentical living donor can be withdrawn from immunosuppressive drugs while maintaining stable graft function within 12 months of hematopoietic stem cell infusion from the same HLA-identical living donor, preceded by conditioning with TLI and ATG.

Sponsor's own description

The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function through hematopoietic stem cell (HPSC) infusion from the same donor. HPSC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

HLA Type and the Effect of HLA Antibodies in Kidney, Liver, and Pancreas Transplantation: A Review.
Zarei E, Roozbeh J, Nikoupour Deylami H, Nikeghbalian S, et al · · 2026 · PMID 42080115 · DOI 10.18502/ajmb.v18i1.21042

Verify or expand the search:

Other recruiting trials for End Stage Kidney Disease

Currently open trials in the same condition.

NCT06356168 — Virtual Reality in End Stage Kidney Disease · NA · recruiting
NCT05715814 — meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis · Phase 3 · recruiting
NCT05642364 — Virtual Reality in Hemodialysis to Improve Psychological Well-being · NA · active not recruiting
NCT05642156 — Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis · NA · recruiting
NCT05311956 — Pain Reduction Using NEurostimulation Study · NA · active not recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05525507 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 21 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525507.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing